Emergent’s approach is to achieve balance in the products that we develop through a pipeline comprising innovative vaccines and therapeutics that target diseases worldwide.
Program
UniFlu
(Universal influenza vaccine)
Pre Clinical
Phase 1
Phase 2
Phase 3
Phase 4
WEVEE VLP
(Western, Eastern and Venezuelan equine encephalitic VLP)
Pre Clinical
Phase 1
Phase 2
Phase 3
Phase 4
EBS-Lassa
(rVSV-vectored vaccine for Lassa fever)
Pre Clinical
Phase 1
Phase 2
Phase 3
Phase 4
EBS-Marburg
(rVSV-vectored vaccine for Marburg virus disease)
Pre Clinical
Phase 1
Phase 2
Phase 3
Phase 4
EBS-Sudan
(rVSV-vectored vaccine for Sudan virus disease)
Pre Clinical
Phase 1
Phase 2
Phase 3
Phase 4
Pan-Ebola mAb
(Ebola/Sudan monoclonal)
Pre Clinical
Phase 1
Phase 2
Phase 3
Phase 4